We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Bausch Health Cos | NYSE:VRX | NYSE | Ordinary Share |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 23.40 | 0.00 | 01:00:00 |
British Columbia, Canada
|
001-14956
|
98-0448205
|
(State or other jurisdiction of
incorporation or organization) |
(Commission File Number)
|
(I.R.S. Employer
Identification Number) |
|
2150 St. Elzéar Blvd. West
Laval, Quebec Canada H7L 4A8 |
|
(Address of Principal Executive Offices)(Zip Code)
|
||
|
514-744-6792
|
|
(Registrant’s telephone number, including area code)
|
||
(Former name or former address, if changed since last report)
|
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
•
|
general unsecured obligations of the Company and the Note Guarantors, as applicable;
|
•
|
pari passu
in right of payment with each other and all existing and future unsubordinated indebtedness of the Company or the applicable Note Guarantor;
|
•
|
senior in right of payment to all existing and future indebtedness of the Company or the applicable Note Guarantor that expressly provides for its subordination to the notes or the applicable guarantee;
|
•
|
structurally subordinated to all existing and future indebtedness and other liabilities of Valeant’s subsidiaries (other than the Company) that do not guarantee the notes; and
|
•
|
effectively subordinated to all existing and future secured indebtedness of the Company or the applicable Note Guarantor, including the Credit Agreement and the Existing Senior Secured Notes, to the extent of the value of the assets securing such indebtedness.
|
•
|
incur or guarantee additional indebtedness;
|
•
|
make certain investments and other restricted payments;
|
•
|
create liens;
|
•
|
enter into transactions with affiliates;
|
•
|
engage in mergers, consolidations or amalgamations; and
|
•
|
transfer and sell assets.
|
Exhibit Number
|
Description
|
4.1
|
Indenture, dated as of March 26, 2018, by and among Valeant Pharmaceuticals International, Valeant Pharmaceuticals International, Inc., the other guarantors party thereto and The Bank of New York Mellon, as trustee.
|
99.1
|
Press release announcing the early tender results and the early settlement date of the tender offers.
|
Exhibit Number
|
Description
|
4.1
|
|
99.1
|
VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
|
|
By:
|
/s/ Paul S. Herendeen
|
|
Paul S. Herendeen
|
|
Executive Vice President and Chief Financial Officer
|
1 Year Valeant Pharma Chart |
1 Month Valeant Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions